25351958|t|The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases.
25351958|a|Macrophages switch to an anti-inflammatory, 'regulatory'-like phenotype characterized by the production of high levels of interleukin (IL)-10 and low levels of pro-inflammatory cytokines to promote the resolution of inflammation. A potential therapeutic strategy for the treatment of chronic inflammatory diseases would be to administer drugs that could induce the formation of 'regulatory'-like macrophages at sites of inflammation. In the present study, we demonstrate that the clinically approved cancer drugs bosutinib and dasatinib induce several hallmark features of 'regulatory'-like macrophages. Treatment of macrophages with bosutinib or dasatinib elevates the production of IL-10 while suppressing the production of IL-6, IL-12p40 and tumour necrosis factor alpha (TNFalpha) in response to Toll-like receptor (TLR) stimulation. Moreover, macrophages treated with bosutinib or dasatinib express higher levels of markers of 'regulatory'-like macrophages including LIGHT, SPHK1 and arginase 1. Bosutinib and dasatinib were originally developed as inhibitors of the protein tyrosine kinases Bcr-Abl and Src but we show that, surprisingly, the effects of bosutinib and dasatinib on macrophage polarization are the result of the inhibition of the salt-inducible kinases. Consistent with the present finding, bosutinib and dasatinib induce the dephosphorylation of CREB-regulated transcription co-activator 3 (CRTC3) and its nuclear translocation where it induces a cAMP-response-element-binding protein (CREB)-dependent gene transcription programme including that of IL-10. Importantly, these effects of bosutinib and dasatinib on IL-10 gene expression are lost in macrophages expressing a drug-resistant mutant of salt-inducible kinase 2 (SIK2). In conclusion, our study identifies the salt-inducible kinases as major targets of bosutinib and dasatinib that mediate the effects of these drugs on the innate immune system and provides novel mechanistic insights into the anti-inflammatory properties of these drugs. 
25351958	30	39	dasatinib	Chemical	MESH:D000069439
25351958	44	53	bosutinib	Chemical	MESH:C471992
25351958	66	78	inflammatory	Disease	MESH:D007249
25351958	163	175	inflammatory	Disease	MESH:D007249
25351958	255	274	interleukin (IL)-10	Gene	3586
25351958	297	319	inflammatory cytokines	Disease	MESH:D000080424
25351958	349	361	inflammation	Disease	MESH:D007249
25351958	425	446	inflammatory diseases	Disease	MESH:D007249
25351958	553	565	inflammation	Disease	MESH:D007249
25351958	633	639	cancer	Disease	MESH:D009369
25351958	646	655	bosutinib	Chemical	MESH:C471992
25351958	660	669	dasatinib	Chemical	MESH:D000069439
25351958	767	776	bosutinib	Chemical	MESH:C471992
25351958	780	789	dasatinib	Chemical	MESH:D000069439
25351958	817	822	IL-10	Gene	3586
25351958	859	863	IL-6	Gene	3569
25351958	868	873	12p40	Chromosome	12
25351958	908	916	TNFalpha	Gene	7124
25351958	1006	1015	bosutinib	Chemical	MESH:C471992
25351958	1019	1028	dasatinib	Chemical	MESH:D000069439
25351958	1112	1117	SPHK1	Gene	8877
25351958	1122	1132	arginase 1	Gene	383
25351958	1134	1143	Bosutinib	Chemical	MESH:C471992
25351958	1148	1157	dasatinib	Chemical	MESH:D000069439
25351958	1230	1237	Bcr-Abl	Gene	25
25351958	1242	1245	Src	Gene	6714
25351958	1293	1302	bosutinib	Chemical	MESH:C471992
25351958	1307	1316	dasatinib	Chemical	MESH:D000069439
25351958	1445	1454	bosutinib	Chemical	MESH:C471992
25351958	1459	1468	dasatinib	Chemical	MESH:D000069439
25351958	1501	1544	CREB-regulated transcription co-activator 3	Gene	64784
25351958	1546	1551	CRTC3	Gene	64784
25351958	1602	1639	cAMP-response-element-binding protein	Gene	1385
25351958	1641	1645	CREB	Gene	1385
25351958	1704	1709	IL-10	Gene	3586
25351958	1741	1750	bosutinib	Chemical	MESH:C471992
25351958	1755	1764	dasatinib	Chemical	MESH:D000069439
25351958	1768	1773	IL-10	Gene	3586
25351958	1852	1875	salt-inducible kinase 2	Gene	23235
25351958	1877	1881	SIK2	Gene	23235
25351958	1967	1976	bosutinib	Chemical	MESH:C471992
25351958	1981	1990	dasatinib	Chemical	MESH:D000069439
25351958	2113	2125	inflammatory	Disease	MESH:D007249
25351958	Positive_Correlation	MESH:C471992	1385
25351958	Positive_Correlation	MESH:C471992	8877
25351958	Positive_Correlation	MESH:D000069439	383
25351958	Negative_Correlation	MESH:D000069439	3569
25351958	Negative_Correlation	MESH:C471992	7124
25351958	Negative_Correlation	MESH:D007249	3586
25351958	Negative_Correlation	MESH:D000069439	25
25351958	Negative_Correlation	MESH:C471992	MESH:D009369
25351958	Positive_Correlation	MESH:C471992	383
25351958	Negative_Correlation	MESH:D000069439	MESH:D009369
25351958	Negative_Correlation	MESH:D000069439	MESH:D007249
25351958	Positive_Correlation	MESH:D000069439	8877
25351958	Comparison	MESH:C471992	MESH:D000069439
25351958	Negative_Correlation	MESH:D000069439	64784
25351958	Negative_Correlation	MESH:D000069439	6714
25351958	Negative_Correlation	MESH:C471992	3569
25351958	Positive_Correlation	MESH:D000069439	1385
25351958	Negative_Correlation	MESH:C471992	64784
25351958	Negative_Correlation	MESH:C471992	25
25351958	Positive_Correlation	MESH:D000069439	3586
25351958	Negative_Correlation	MESH:C471992	MESH:D007249
25351958	Negative_Correlation	MESH:D000069439	7124
25351958	Association	1385	3586
25351958	Positive_Correlation	MESH:C471992	3586
25351958	Negative_Correlation	MESH:C471992	6714

